Neurocentrx Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
9
Neurocentrx General Information
Description
Developer of oral delivery medicines designed to treat patients with neurological conditions. The company's medicines are oral ketamine formulations that treat central nervous system conditions and cancer-related pain, enabling patients to alleviate severe and chronic neuropathic pain conditions.
Contact Information
Website
www.neurocentrx.comCorporate Office
- Level 5
- 9 Haymarket Square
- Edinburgh EH3 8RY
- Scotland, United Kingdom
Corporate Office
- Level 5
- 9 Haymarket Square
- Edinburgh EH3 8RY
- Scotland, United Kingdom
Neurocentrx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series A) | Upcoming | Clinical Trials - Phase 2 | ||||
| 8. Later Stage VC | 23-Sep-2025 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 12-May-2022 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 28-Feb-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC | 23-May-2017 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC | 29-Apr-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC | 31-Mar-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 25-Mar-2014 | $482K | $482K | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | 18-Jul-2013 | Completed | Clinical Trials - Phase 1 |
Neurocentrx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 465,418 | $0.000010 | $0.56 | $0.56 | 1x | $0.56 | 5.17% | |
| Ordinary | 1,481,933 | $0.000010 | $0.34 | $0.34 | 1x | $0.34 | 16.47% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neurocentrx Patents
Neurocentrx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202019952-D0 | Novel compositions | Inactive | 17-Dec-2020 | ||
| AU-2021404187-A1 | Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders | Pending | 17-Dec-2020 | ||
| AU-2021404187-A9 | Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders | Pending | 17-Dec-2020 | ||
| CA-3202522-A1 | Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders | Pending | 17-Dec-2020 | ||
| EP-4262769-A1 | Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders | Pending | 17-Dec-2020 | A61K31/135 |
Neurocentrx Signals
Neurocentrx Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| SPRIM Global Investments | Holding Company | Minority | ||
| Wellcome Trust | Limited Partner | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| Neo Kuma Ventures | Venture Capital | Minority | ||
| O2h Ventures | Venture Capital | Minority |
Neurocentrx FAQs
-
When was Neurocentrx founded?
Neurocentrx was founded in 2013.
-
Where is Neurocentrx headquartered?
Neurocentrx is headquartered in Edinburgh, United Kingdom.
-
What is the size of Neurocentrx?
Neurocentrx has 6 total employees.
-
What industry is Neurocentrx in?
Neurocentrx’s primary industry is Drug Discovery.
-
Is Neurocentrx a private or public company?
Neurocentrx is a Private company.
-
What is Neurocentrx’s current revenue?
The current revenue for Neurocentrx is .
-
How much funding has Neurocentrx raised over time?
Neurocentrx has raised $6.15M.
-
Who are Neurocentrx’s investors?
SPRIM Global Investments, Wellcome Trust, Meltwind Advisory, Neo Kuma Ventures, and O2h Ventures are 5 of 9 investors who have invested in Neurocentrx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process